What Does the Yesafili Launch Mean for Ophthalmology Billing?
Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea 2 mg that Biocon launched in the United States on August 3, 2026. As of August 2026, it is the first interchangeable aflibercept biosimilar that practices can actually buy and bill, and it carries its own HCPCS code, Q5155. Every ophthalmology practice that administers anti-VEGF injections now faces new decisions on code selection, payer coverage, and reimbursement.
New code, not J0178. Yesafili is billed under Q5155, not the Eylea code J0178. Submitting a biosimilar on the reference-product code draws an immediate denial.
Coverage is not automatic. A permanent HCPCS code does not mean the payer covers the drug. Several plans place a newly launched biosimilar in a review status before they pay it.
Interchangeable is a pharmacy term. For a physician-administered, buy-and-bill drug, interchangeability rarely changes what you order. Payer formulary and step therapy drive the choice.
A Second Eylea Biosimilar Reaches the Market
On August 3, 2026, Biocon announced the US commercial launch of Yesafili, its interchangeable biosimilar to Regeneron’s Eylea 2 mg. The FDA approved Yesafili back in May 2024 and granted it an interchangeable designation, but a US launch was held up by patent litigation that settled in April 2025. That settlement cleared the path for the second-half-2026 launch we are now seeing.
Yesafili is only the second aflibercept 2 mg biosimilar to actually reach the US market, following Amgen’s Pavblu in October 2024, and it is the first product carrying an interchangeable designation to launch commercially. More aflibercept biosimilars are queued behind it, with Ahzantive, Enzeevu, Eydenzelt, and additional entrants expected in late 2026. In short, the anti-VEGF market that ran on one dominant brand for years is fragmenting fast, and the pace is only picking up.
For context on why this matters to the money side of a practice, aflibercept sat near the top of Medicare Part B drug spending in ophthalmology for most of the last decade. Eylea itself is not going away, and the higher-dose Eylea HD (an 8 mg product on its own code, J0177) is a separate track that biosimilars do not touch. But every additional 2 mg biosimilar gives payers another lever to steer utilization through formulary placement and step therapy, which means the product on your shelf and the product your payer prefers may not line up.
Here is the operational catch that trips up practices. CMS assigned Yesafili its permanent HCPCS code, Q5155, effective October 1, 2025, roughly ten months before the drug was available to purchase. The code has been sitting in the code set, but the billing question only becomes live now that the product can be stocked and administered. For a refresher on how CPT and HCPCS codes flow through an eye claim, our ophthalmology medical billing and coding guideline walks through the basics.
Which Ophthalmology Practices Does This Affect?
This change reaches any practice that administers intravitreal anti-VEGF therapy: retina specialists first, but also comprehensive ophthalmologists who treat wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. If your practice bills J0178 today, you have a decision to make on every future injection claim.
Aflibercept is one of the highest-spend physician-administered drugs in all of ophthalmology, which is exactly why a biosimilar shift moves revenue quickly. Across the billing companies we vet, retina-heavy practices routinely carry more drug-cost dollars on a single claim than almost any other ophthalmology service, so a coding or coverage error on an anti-VEGF line is not a small write-off. It can be several hundred dollars per injection, multiplied across a busy injection clinic.
The volume is what makes it add up. A single wet AMD patient can receive frequent injections in a maintenance year, and many payer policies allow dosing up to roughly 12 times per year per eye. A clinic managing hundreds of active injection patients is therefore submitting thousands of high-dollar drug lines a year. When the code, units, or coverage status is wrong on even a small percentage of those, the dollars lost outpace almost any coding fix elsewhere in the practice.
The imaging that accompanies these visits is affected too, because the drug line rarely travels alone. A typical injection visit also carries diagnostic imaging such as OCT of the retina, billed with CPT 92134 for OCT of the retina. When the drug code changes, the whole claim needs a second look to make sure the imaging, the injection, and the drug all post cleanly together.
Each Aflibercept Biosimilar Has Its Own Code
Biosimilars do not work like small-molecule generics. There is no single shared code that all versions of aflibercept fall under. Each biosimilar receives its own unique HCPCS code, and the reference product keeps its own. That means the code on your claim has to match the exact product on the vial you administered, brand for brand.
The table below maps the current aflibercept family. All of these products are billed per 1 mg, so a standard 2 mg dose is reported as 2 units. Every claim also requires the drug’s NDC and is submitted alongside the intravitreal injection code, CPT 67028, with an RT or LT laterality modifier.
One more detail that causes clean-looking claims to deny: the NDC on the claim has to match the specific product tied to the Q-code, down to the exact package administered. Because these are single-dose vials, the NDC, the units, and the waste reporting all have to agree with each other. If the drug library maps a biosimilar NDC to the wrong Q-code, the claim can pass an internal edit and still deny at the payer, which is the hardest kind of error to catch after the fact.
| Brand | Nonproprietary name | HCPCS | Status and billing note |
|---|---|---|---|
| Eylea | aflibercept | J0178 | Reference product, billed per 1 mg |
| Eylea HD | aflibercept hd | J0177 | 8 mg high-dose product, separate code, not a biosimilar |
| Pavblu | aflibercept-ayyh | Q5147 | First aflibercept biosimilar to launch (2024), not interchangeable |
| Yesafili | aflibercept-jbvf | Q5155 | Launched August 3, 2026, interchangeable designation |
| Opuviz | aflibercept-yszy | Q5153 | Interchangeable, US launch expected |
| Enzeevu | aflibercept-abzv | Q5149 | US launch expected in late 2026 |
| Ahzantive | aflibercept-mrbb | Q5150 | US launch expected in late 2026 |
| Eydenzelt | aflibercept-boav | Q5170 | HCPCS code effective July 1, 2026 |
Codes reflect the CMS HCPCS Level II code set and current payer drug lists as of August 2026. Confirm each payer’s accepted code before submitting, since coverage can lag code assignment.
How Are Aflibercept Biosimilars Reimbursed?
Under Medicare Part B, aflibercept biosimilars are paid using the Average Sales Price methodology. The biosimilar is reimbursed at its own ASP plus an add-on payment that is calculated on the reference product’s ASP, not on the biosimilar’s lower price. That detail matters because the add-on does not shrink just because the biosimilar costs less.
The larger wrinkle is timing. A newly launched drug has no ASP for its first few quarters, so CMS prices it from wholesale acquisition cost until real ASP data accumulates. In practice, that means the allowed amount on a brand-new biosimilar can move from one quarter to the next, and a number you confirmed in one quarter may not hold in the next.
Federal policy has also created a temporary enhanced add-on for certain qualifying biosimilars, intended to encourage adoption over the reference product. Whether a given aflibercept biosimilar qualifies, and for how long, is worth confirming rather than assuming, because it changes the margin math directly. The takeaway is that biosimilar reimbursement is not a set-it-and-forget-it number. It has to be watched, and the practices that watch it are the ones that actually capture the savings a biosimilar is supposed to deliver.
For a busy clinic, model this before you switch. A practice running several hundred injections a quarter needs to compare its acquisition cost per unit against the allowed amount per unit for each product, because a biosimilar with a lower purchase price does not automatically mean a better margin once the add-on and payer contract are factored in. This is the kind of drug-cost math that sits at the center of revenue cycle management for any injection-heavy practice.
What to Do Before Your First Biosimilar Claim
Providers often come to us after a string of denials on a newly launched drug, when the fix would have taken an hour of setup beforehand. Work through these steps before you administer a biosimilar for the first time.
- Confirm the exact HCPCS code for the product you stock. Match the Q-code to the brand on the vial, since aflibercept biosimilars do not share a code.
- Check each payer’s coverage status. Verify whether the plan lists the biosimilar as covered, preferred, or still under launch review before you administer it.
- Update your chargemaster and drug library. Load the correct Q-code, NDC, and per-milligram unit conversion so claims do not default back to J0178.
- Verify step-therapy and prior-authorization rules. Some plans now require the biosimilar first, while others still require the reference product, and those are opposite mistakes.
- Set the units correctly. Report 2 units for a standard 2 mg dose, and apply the JW or JZ modifier for any discarded or zero-discarded drug from a single-dose vial.
- Attach the injection code and laterality. Bill CPT 67028 on the same claim with RT or LT, since a missing modifier denies the administration line.
- Track ASP updates each quarter. New biosimilars reprice as ASP data accrues, so revisit your expected reimbursement rather than assuming it holds all year.
None of these steps is difficult on its own. The problem is that they have to be done for each product and repeated for every payer, which is exactly the kind of task that slips when a busy clinic is focused on patient care rather than payer bulletins. Building them into a standing pre-launch checklist is what keeps a biosimilar rollout from turning into a denial cleanup.
Not sure your billing setup is ready for the biosimilar shift? Get matched with a vetted ophthalmology billing partner that already tracks anti-VEGF coding and payer coverage for you.
Common Biosimilar Billing Mistakes
The most common issue we see after any anti-VEGF launch is a practice that stocks the new product before confirming payer coverage, then absorbs a month of denials before anyone connects the dots. A permanent HCPCS code feels like a green light, but the payer side often is not ready yet.
Watch for a review status specifically. Some plans place a newly launched biosimilar on a Review at Launch list, which excludes the drug from the medical benefit or forces it onto unclassified codes such as C9399, J3490, or J3590 until the plan finishes its own evaluation. Billing Q5155 to a plan that has not yet loaded it can deny even when the code itself is valid.
The other recurring errors are mechanical and preventable. Defaulting to the Eylea code J0178 out of habit is the most frequent, because staff who have billed aflibercept the same way for years do not always register that the product on the shelf changed. Reporting the wrong number of units is next, usually a single unit instead of two for a 2 mg dose. Omitting the NDC, or attaching an NDC that does not match the Q-code, quietly denies claims that otherwise look complete.
Two more are worth calling out. Skipping JW or JZ waste reporting on single-dose vials invites audit exposure on exactly the kind of high-dollar drug that auditors look at first. And assuming a biosimilar can be freely alternated with other anti-VEGF agents is risky, because many payers review agent switching case by case and may deny a switch that was not documented as medically necessary. None of these are exotic. They are the everyday details that decide whether a biosimilar transition saves money or costs it.
Does Interchangeability Let a Pharmacy Swap My Drug?
This is the point that causes the most confusion, so it is worth separating cleanly. An interchangeable designation is an FDA status that allows a pharmacist to substitute the biosimilar for the reference product at the pharmacy counter without prescriber involvement, subject to state law, much like a generic substitution.
For a physician-administered, buy-and-bill drug like intravitreal aflibercept, you purchase the product and administer it in the office, so the pharmacy-counter substitution mechanism generally does not apply to your workflow. What actually determines which product you use is your payer’s formulary, its step-therapy rules, and your own acquisition economics. Treat interchangeability as a marketing and pharmacy fact, not as a billing instruction for your injection claims.
A quick scenario makes the distinction concrete. Suppose a sales sheet tells your office that Yesafili is interchangeable with Eylea. That is true, but it does not mean your claim will pay, and it does not mean you can swap products mid-treatment without consequence. If the patient’s plan still prefers the reference product, or lists the biosimilar under a launch review, billing the biosimilar can deny regardless of its interchangeable status. The designation answers a pharmacy question. Your claim answers a payer-policy question, and those two are decided in different places.
In-House vs Outsourced Biosimilar Billing
A single new drug code sounds manageable. The reality is a moving grid: several aflibercept products, each with its own Q-code, each with different coverage across Medicare, Medicare Advantage, and commercial plans, each repricing quarter to quarter, and some sitting in launch-review status at any given time. A solo biller tracking all of that by hand will miss something.
In our experience matching providers with billing partners, the companies that handle biosimilars cleanly build these checks as automated claim-scrubbing rules rather than manual lookups. Across the network, practices that move to a specialized partner see denial rates fall by roughly 5 to 7 percent within the first 90 days, and many identify reimbursement gains of up to 20 percent by the time contracts come up for renegotiation. This is the kind of payer-tracking discipline our reviewer, Tim Daniels, Director of Strategic Accounts at Billing Service Quotes, points to as the difference between a clean drug transition and a quarter of denials.
You do not have to hand off the whole revenue cycle to benefit. Even a practice that keeps billing in-house can use a vetted partner to audit its anti-VEGF setup before the next biosimilar lands, which is where most of the avoidable losses happen. Ophthalmology Bill Co connects practices with a network of more than 30 ophthalmology-certified billing companies across all 50 states, and once a practice is verified, the matched partner typically makes contact within about two hours. With several more aflibercept biosimilars expected before the end of 2026, getting that review done now is far cheaper than reworking a quarter of denied injection claims later.
Frequently Asked Questions
Yesafili (aflibercept-jbvf) is billed with HCPCS code Q5155, which became effective October 1, 2025. The drug is reported per 1 mg, so a standard 2 mg intravitreal dose is submitted as 2 units, along with the product’s NDC and the injection code.
No. J0178 is the reference product code for Eylea. Each aflibercept biosimilar has its own unique HCPCS code, and submitting a biosimilar on the reference-product code will trigger a denial. Match the code to the exact product administered.
Two units. Aflibercept and its biosimilars are all billed per 1 mg, so a standard 2 mg intravitreal injection is reported as 2 units. Any discarded drug from a single-dose vial is reported with the JW modifier, or JZ when there is zero discard.
Coverage varies by payer and is not guaranteed by the existence of a code. Some plans cover it immediately, while others place a newly launched biosimilar in a review status first. Verify each payer’s coverage and any step-therapy requirement before administering it.
Interchangeable is an FDA designation that allows pharmacy-level substitution under state law. For a physician-administered, buy-and-bill drug, that substitution mechanism generally does not apply, so your product choice is driven by payer formulary and step therapy, not by the interchangeable status.
Yes. The intravitreal injection itself is billed with CPT 67028 regardless of which anti-VEGF product is used, submitted on the same claim as the drug with an RT or LT laterality modifier. Only the drug code changes when you switch to a biosimilar.
It is a payer designation that excludes a newly launched drug from the medical benefit, or routes it to unclassified codes such as C9399 or J3490, until the plan completes its own clinical and coverage review. Claims can deny during this window even when the permanent code is valid.
Next Steps
- If you are moving to a biosimilar, start by verifying payer coverage and loading the correct Q-code, NDC, and units into your drug library.
- Review how imaging posts on injection visits with our guide to CPT 92134 for OCT of the retina.
- Pressure-test your denial rate on high-cost drugs with our ophthalmology revenue cycle management guide.
The aflibercept market is only getting more crowded, with more biosimilars landing through late 2026. Get matched with an ophthalmology billing partner that keeps your anti-VEGF coding, coverage, and reimbursement clean as the codes multiply.
